Since the publication of DrugBank 5.0, there have been 3161 new investigational/experimental (phase III or earlier) drugs added across all supported geographic regions, bringing the total number of such drugs in DrugBank to 11 262. Of these, 1747 are small molecule drugs while the other 1414 are biotech drugs. These drugs are largely added based on imports from clinicaltrials.gov, wherein drug-based interventions that do not have an existing match in DrugBank prompt the creation of new DrugCards. Additionally, the DrugBank curation team routinely monitors upcoming potential approvals based on positive clinical trial results and expend additional effort to curate information for these entries ahead of formal regulatory approval.
